Cystitis News and Research

Latest Cystitis News and Research

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor. The funds will be used to advance its lead program, TTI-1612, into clinical trials for the treatment of interstitial cystitis, also known as bladder pain syndrome. The first trial is projected to start in the second half of this year.

12 May 2011

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.

25 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

TARIS Biomedical, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS' innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC.

10 Mar 2011

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.

14 Dec 2010

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that preliminary results from its cancer stem cell program, targeting the CD47 protein, will be reported in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida, December 4-7, 2010.

2 Dec 2010

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Watson Pharmaceuticals, Inc. today announced that the U.S. pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

11 Nov 2010

Amgen wins Scrip Best New Drug award for Prolia

Amgen is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

8 Nov 2010

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Men with prostate cancer treated with a specialized type of radiation called intensity modulated radiation therapy (IMRT) have fewer gastrointestinal complications compared to patients treated with conventional three-dimensional conformal radiotherapy (3D-CRT), according to a study presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending more advanced care to more patients. Clinicians at the hospital have used RapidArc® radiotherapy from Varian Medical Systems to treat patients for cancers of the nasopharynx, cervix, breast, and lung.

11 Oct 2010

Early diagnosis of interstitial cystitis can improve quality of life

October is interstitial cystitis (IC) awareness month and this year's campaign is dedicated to fighting discrimination.

5 Oct 2010

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Afflicting countless people worldwide, chronic pain is a largely misunderstood and under-treated disease that forever alters the lives of more than 50 million Americans each year.

28 Sep 2010

MediciNova receives FDA approval to proceed with initial trial of ibudilast

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported FDA's approval to proceed with an initial trial of the company's neurological drug candidate, ibudilast (MN-166/AV411), as a potential new pharmacotherapy for methamphetamine addiction.

27 Sep 2010

HRA Pharma, Watson enter licensing agreement for ulipristal acetate emergency contraceptive commercialization

HRA Pharma, a privately-held, European pharmaceutical company that develops healthcare solutions in reproductive health and endocrinology and makes them available worldwide, and Watson Pharmaceuticals, Inc. announced today that they have entered into a licensing agreement for the commercialization of HRA Pharma's next generation emergency contraceptive ulipristal acetate in Canada.

18 Sep 2010

National Health Information Resource Center honors Interstitial Cystitis Association for special publication

The Interstitial Cystitis Association, the only nonprofit health association dedicated solely to improving the lives of those affected by interstitial cystitis (IC), was recently honored with an award from the National Health Information Resource Center. The organization received honors for a special issue of its ICA Update – a quarterly magazine focused on current IC research, treatment, and lifestyle issues.

2 Sep 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.

16 Aug 2010

Severe inflammatory response to initial UTI causes bladder damage: Research

The immune system may open the door to recurrent urinary tract infections (UTIs) by overdoing its response to an initial infection, researchers at Washington University School of Medicine in St. Louis have found.Researchers showed in mice that severe inflammatory responses to an initial UTI cause bladder damage and allow infection to persist longer. After one to two weeks of infection, the bladder wall undergoes additional changes that leave mice more vulnerable to later infection. Suppressing the immune system during initial infection decreases these vulnerabilities, they report Aug. 12 in PLoS Pathogens.

13 Aug 2010

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Watson Pharmaceuticals, Inc. today announced an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals, Inc., a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero's Recombinant Follicle Stimulating Hormone. The product is currently in preclinical development as a biosimilar molecule for the treatment of female infertility.

15 Jul 2010

Cystitis News and Research

Latest Cystitis News and Research

Lx Therapies, BioCis partner to form Laurantis Pharma

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Amgen wins Scrip Best New Drug award for Prolia

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Early diagnosis of interstitial cystitis can improve quality of life

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

MediciNova receives FDA approval to proceed with initial trial of ibudilast

HRA Pharma, Watson enter licensing agreement for ulipristal acetate emergency contraceptive commercialization

National Health Information Resource Center honors Interstitial Cystitis Association for special publication

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Severe inflammatory response to initial UTI causes bladder damage: Research

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cystitis News and Research

Latest Cystitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in